These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16103107)

  • 1. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.
    Haiman CA; Stram DO; Cheng I; Giorgi EE; Pooler L; Penney K; Le Marchand L; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1021-5. PubMed ID: 16702386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
    Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
    Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer.
    Setiawan VW; Cheng I; Stram DO; Giorgi E; Pike MC; Van Den Berg D; Pooler L; Burtt NP; Le Marchand L; Altshuler D; Hirschhorn J; Henderson BE; Haiman CA
    Cancer Res; 2006 Dec; 66(24):12019-25. PubMed ID: 17178901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
    Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
    J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in TP53 and risk of breast cancer in a population-based case control study.
    Sprague BL; Trentham-Dietz A; Garcia-Closas M; Newcomb PA; Titus-Ernstoff L; Hampton JM; Chanock SJ; Haines JL; Egan KM
    Carcinogenesis; 2007 Aug; 28(8):1680-6. PubMed ID: 17449902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for XRCC4 in age at diagnosis and breast cancer risk.
    Allen-Brady K; Cannon-Albright LA; Neuhausen SL; Camp NJ
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1306-10. PubMed ID: 16835328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.
    Soucek P; Borovanova T; Pohlreich P; Kleibl Z; Novotny J
    Breast Cancer Res Treat; 2007 Jun; 103(2):219-24. PubMed ID: 17039264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP3 germline polymorphisms are not associated with risk of breast cancer.
    Raskin L; Rennert G; Gruber SB
    Cancer Genet Cytogenet; 2009 Apr; 190(1):40-2. PubMed ID: 19264232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
    Cox DG; Blanché H; Pearce CL; Calle EE; Colditz GA; Pike MC; Albanes D; Allen NE; Amiano P; Berglund G; Boeing H; Buring J; Burtt N; Canzian F; Chanock S; Clavel-Chapelon F; Feigelson HS; Freedman M; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel L; Kraft P; LeMarchand L; Lund E; Palli D; Peeters PH; Riboli E; Stram DO; Thun M; Tjonneland A; Trichopoulos D; Yeager M;
    Breast Cancer Res; 2006; 8(5):R54. PubMed ID: 16987421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common genetic variation in calpain-10 gene (CAPN10) and diabetes risk in a multi-ethnic cohort of American postmenopausal women.
    Song Y; You NC; Hsu YH; Sul J; Wang L; Tinker L; Eaton CB; Liu S
    Hum Mol Genet; 2007 Dec; 16(23):2960-71. PubMed ID: 17855447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk.
    Yang R; Chen B; Hemminki K; Wappenschmidt B; Engel C; Sutter C; Ditsch N; Weber BH; Niederacher D; Arnold N; Meindl A; Bartram CR; Schmutzler RK; Burwinkel B
    Breast Cancer Res Treat; 2009 Nov; 118(2):407-13. PubMed ID: 19229607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
    Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
    Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
    Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.